VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 665 filers reported holding VANECK VECTORS ETF TR in Q3 2020. The put-call ratio across all filers is 1.01 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $119,310 | -10.6% | 4,434 | 0.0% | 0.05% | -10.7% |
Q2 2023 | $133,498 | +93255.2% | 4,434 | 0.0% | 0.06% | -13.8% |
Q1 2023 | $143 | +12.6% | 4,434 | 0.0% | 0.06% | +4.8% |
Q4 2022 | $127 | -99.9% | 4,434 | +1.6% | 0.06% | -26.2% |
Q3 2022 | $105,000 | -11.8% | 4,364 | 0.0% | 0.08% | +71.4% |
Q2 2022 | $119,000 | -28.7% | 4,364 | 0.0% | 0.05% | -23.4% |
Q1 2022 | $167,000 | -88.2% | 4,364 | -90.2% | 0.06% | -89.7% |
Q4 2021 | $1,421,000 | -40.7% | 44,357 | -45.5% | 0.62% | -43.8% |
Q3 2021 | $2,398,000 | -9.2% | 81,373 | +4.7% | 1.10% | -13.1% |
Q2 2021 | $2,640,000 | +236.3% | 77,701 | +221.6% | 1.27% | +256.7% |
Q1 2021 | $785,000 | +220.4% | 24,158 | +254.7% | 0.36% | +215.0% |
Q4 2020 | $245,000 | -15.2% | 6,810 | -7.6% | 0.11% | -30.2% |
Q3 2020 | $289,000 | -21.5% | 7,372 | -26.5% | 0.16% | -28.9% |
Q2 2020 | $368,000 | +23.5% | 10,027 | -1.5% | 0.23% | +17.5% |
Q4 2019 | $298,000 | – | 10,177 | – | 0.19% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |